Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11046026rdf:typepubmed:Citationlld:pubmed
pubmed-article:11046026lifeskim:mentionsumls-concept:C0330390lld:lifeskim
pubmed-article:11046026lifeskim:mentionsumls-concept:C0022688lld:lifeskim
pubmed-article:11046026lifeskim:mentionsumls-concept:C0007589lld:lifeskim
pubmed-article:11046026lifeskim:mentionsumls-concept:C1868500lld:lifeskim
pubmed-article:11046026lifeskim:mentionsumls-concept:C1149189lld:lifeskim
pubmed-article:11046026lifeskim:mentionsumls-concept:C1515021lld:lifeskim
pubmed-article:11046026lifeskim:mentionsumls-concept:C1705938lld:lifeskim
pubmed-article:11046026lifeskim:mentionsumls-concept:C1511938lld:lifeskim
pubmed-article:11046026lifeskim:mentionsumls-concept:C1711351lld:lifeskim
pubmed-article:11046026lifeskim:mentionsumls-concept:C1527178lld:lifeskim
pubmed-article:11046026lifeskim:mentionsumls-concept:C0591833lld:lifeskim
pubmed-article:11046026pubmed:issue9lld:pubmed
pubmed-article:11046026pubmed:dateCreated2000-11-3lld:pubmed
pubmed-article:11046026pubmed:abstractTextThe cytokine IL-12 manifests its biological activity via interaction with a heterodimeric receptor (IL-12R) present on activated T and NK cells. The cDNAs for two IL-12R subunits have been cloned from human and mouse and designated IL-12Rbeta1 and IL-12Rbeta2. The expression of IL-12Rbeta2 on T cells is influenced by cytokines, particularly IL-4, IL-12, and IFN-gamma; however, little is known regarding regulation of IL-12R expression on NK cells. In this study we show that murine NK cells differentiate into IL-12Rbeta2(low) and IL-12Rbeta2(high) subsets after in vitro stimulation with IL-2 in the absence of exogenous polarizing cytokines. Subset development occurs gradually as NK cells expand in vitro and is generally complete by 8-12 days of culture. Once established, IL-12Rbeta2(low) and IL-12Rbeta2(high) subsets are highly stable in vitro and can be maintained for at least 20 days after FACS sorting. Formation of these NK subsets appears to be strain independent. Flow cytometric analyses demonstrate that both subsets express a number of NK-associated markers, including NK1.1, DX-5, Ly-49A, and Ly-49C, but that the Ly-49G2 class I inhibitory receptor is expressed predominantly on the IL-12Rbeta2(high) population. Both IL-12Rbeta2(low) and IL-12Rbeta2(high) NK cells respond to exogenous IL-12 by rapid production of high levels of IFN-gamma and increased lytic activity against NK-sensitive YAC-1 target cells. Analyses of cytokine gene expression by RNase protection assay indicated that similar to the recently described human NK1 subset, both IL-12Rbeta2(high) and IL-12Rbeta2(low) murine NK subsets expressed high levels of IFN-gamma, whereas neither subset expressed mRNA for the NK2-associated cytokines IL-5 and IL-13.lld:pubmed
pubmed-article:11046026pubmed:languageenglld:pubmed
pubmed-article:11046026pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046026pubmed:citationSubsetAIMlld:pubmed
pubmed-article:11046026pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046026pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046026pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046026pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046026pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046026pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046026pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046026pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046026pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046026pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046026pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046026pubmed:statusMEDLINElld:pubmed
pubmed-article:11046026pubmed:monthNovlld:pubmed
pubmed-article:11046026pubmed:issn0022-1767lld:pubmed
pubmed-article:11046026pubmed:authorpubmed-author:WebbJ RJRlld:pubmed
pubmed-article:11046026pubmed:authorpubmed-author:FilionL GLGlld:pubmed
pubmed-article:11046026pubmed:authorpubmed-author:ChakirHHlld:pubmed
pubmed-article:11046026pubmed:authorpubmed-author:CamilucciA...lld:pubmed
pubmed-article:11046026pubmed:issnTypePrintlld:pubmed
pubmed-article:11046026pubmed:day1lld:pubmed
pubmed-article:11046026pubmed:volume165lld:pubmed
pubmed-article:11046026pubmed:ownerNLMlld:pubmed
pubmed-article:11046026pubmed:authorsCompleteYlld:pubmed
pubmed-article:11046026pubmed:pagination4985-93lld:pubmed
pubmed-article:11046026pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:meshHeadingpubmed-meshheading:11046026...lld:pubmed
pubmed-article:11046026pubmed:year2000lld:pubmed
pubmed-article:11046026pubmed:articleTitleDifferentiation of murine NK cells into distinct subsets based on variable expression of the IL-12R beta 2 subunit.lld:pubmed
pubmed-article:11046026pubmed:affiliationDepartment of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, Ontario, Canada.lld:pubmed
pubmed-article:11046026pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11046026pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:11046026pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11046026lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11046026lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11046026lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11046026lld:pubmed